Molecules, Machines & Markets: Biotech Booms, AI Accelerates, and Pain Relief Gets Personal

October 16, 2025

DENVER, Colo., Oct 16, 2025 (247marketnews.com)- Wall Street opens today with biotech and AI stocks in sharp focus after a wave of clinical milestones, cutting-edge launches, and strategic shifts dominated headlines. Here’s what’s moving the markets this morning:

MIRA Pharmaceuticals (NASDAQ:MIRA) is making waves in the $70B non-opioid pain market after announcing that its oral drug candidate Mira-55 outperformed injected morphine in normalizing pain and reducing inflammation in a validated preclinical model. Unlike opioids, Mira-55 acts directly via CB2 receptors, addressing both pain perception and its inflammatory cause.

This study marks the first time the company directly measured inflammation alongside pain, strengthening the rationale for its planned Investigational New Drug (IND) filing targeting chronic inflammatory pain. With oral administration and dual-mechanism action, Mira-55 is positioning itself as a powerful non-opioid contender.

Kraig Biocraft Labs (OTCQB:KBLB) unveiled BAM 1 Alpha, a genetically enhanced spider silk hybrid boasting 245% improved vigor and 22% greater cocoon shell weight. The breakthrough advances commercialization potential in defense, biomedical, and performance textiles. Market watchers are paying attention and the biotech buzz is back.

bioAffinity Technologies (NASDAQ:BIAF) secured a patent allowance for its AI-powered CyPath Lung test, which uses flow cytometry and machine learning to detect early-stage lung cancer. The newly approved U.S. patent strengthens its international portfolio and adds protection for its diagnostic algorithm, capable of identifying Stage 1A lung cancer with 92% sensitivity and 87% specificity.

SOPHiA GENETICS (NASDAQ:SOPH) rolled out SOPHiA DDM Digital Twins, a tech platform simulating patient-specific outcomes using multimodal data. The goal: better, faster oncology decisions. Clinicians can now model real-time treatment responses using AI-generated patient avatars. The feature launches with lung cancer, with more indications on deck. As AI enters the oncologist’s toolkit, SOPHiA is out front in real-world precision medicine.

At today’s R&D Day in NYC, Cellectis (NASDAQ:CLLS) is highlighting the complete Phase 1 dataset for lasme-cel (UCART22) in relapsed/refractory B-ALL. The clinical-stage gene editing firm is detailing its pivotal Phase 2 design, reinforcing its long-term commercial vision and platform potential in next-gen allogeneic CAR-T therapies.

Vivakor (NASDAQ:VIVK) remains on radar after refining its oil remediation and heavy oil extraction tech. With domestic energy chatter heating up into Q4, its Utah-based activities are being reassessed in light of geopolitical shifts and energy security themes.

Sunshine Biopharma’s (NASDAQ:SBFM) Nora Pharma subsidiary launched Pravastatin, a generic of Pravachol®, into the Canadian market. As the $582M Canadian lipid drug market surges toward $1B by 2033, SBFM taps into cardiovascular drug demand with 10, 20, and 40 mg doses now available.

In a multi-year pact, Tempus AI (NASDAQ:TEM) will provide real-world multimodal datasets to guide biomarker-driven clinical trials across Whitehawk Therapeutics’ (NASDAQ:WHWK) ADC pipeline, targeting cancers like lung and gynecologic tumors. The partnership is data-driven, targeting RNA-based biomarker validation and smarter patient targeting.

NUBURU (NYSE:BURU) resolved a disclosure delay and is back in compliance with NYSE American requirements. Under dual-CEO leadership, it’s expanding its blue-laser tech into defense and industrial markets, aided by active acquisitions, including a recent deal to acquire Orbit, a SaaS defense software firm. BURU’s roadmap reflects an aggressive transformation strategy.

Beyond Meat (NASDAQ:BYND) reached a 52-week low, again showing that science without market demand can be a losing recipe. As plant-based enthusiasm cools, investors are shifting to real science with clear therapeutic or technological value.

For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com

Please click here to read the full Kraig Labs analyst report on 247marketnews.com.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, MIRA, BIAF, SOPH, SBFM, BYND)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.